Education
M.D. Inner Mongolia Medical University, 1996
Ph.D. Peking University, 2003
M.B.A. University of South Alabama, 2012
Areas of Expertise
Translational research in breast cancer and colorectal cancer, delving into the underlying mechanisms of cancer initiation and progression, while devising effective strategies to impede these processes.
Cancer drug development and the investigation of molecular mechanisms involving microRNA in the anti-cancereffects of nonsteroidal anti-inflammatory drugs (NSAIDs).
Research Interests
Cancer drug development and the investigation of molecular mechanisms involving microRNA in the anti-cancer effects of non-steroidal anti-inflammatory drugs (NSAIDs)
Exploring the potential of NSAIDs as novel immune modulators to enhance the response of triple negative breast cancer and colorectal cancer to immune checkpoint inhibitors.
Cancer Therapeutics , Cancer Chemoprevention, Tumor Metastasis, Cancer Drug Discovery and Development, Health Disparities, Immunotherapy
Selected Publications
Bin Yi, Yu Xun, Hao Cheng, Qingzhao Yu, Augusto Ochoa, Adam Riker, Yaguang Xi*. 2021. Sulindac modulatesthe response of proficient MMR colorectal cancer to anti-PD-L1 immunotherapy. Molecular Cancer Therapeutics.20(7):1295-1304.
Hongyou Zhao, Bin Yi, Zhipin Liang, Ches’Nique Phillips, Hui-Yi Lin, Adam I. Riker, Yaguang Xi*. 2021. Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer. Genes and Diseases. 8 (3): 320-330.
Zhipin Liang, Zhiqiang Qin, Adam Riker, Yaguang Xi*.2020. CRISPR/ Cas9 ablating viral microRNA promotes lyticreactivation of Kaposi’s sarcoma-associated herpesvirus. Biochem Biophys Res Commun. 533 (4):1400-1405.
